Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Why Pfizer’s R&D Chief Dolsten Is Enthusiastic About Allergan

This article was originally published in The Pink Sheet Daily

Executive Summary

President-Worldwide R&D Mikael Dolsten talked in an interview at J.P. Morgan about the research opportunities for a combined Pfizer/Allergan – and bridging two different approaches to R&D.

You may also be interested in...



J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases

The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.

Neurocrine Gains Clinical-Stage Schizophrenia Candidates Returned To Sosei By AbbVie

Deal Snapshot: Neurocrine expanded its pipeline with rights to subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei.

No Way To Go But Grow: J&J Outlines Plans To Become A $60bn Pharma In 2025

Management outlined its growth strategy to investors, highlighting plans to file 14 novel drugs with more than $1bn in peak sales by 2025.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel